1 BTC
=
- USD
Elicio Therapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Elicio Therapeutics, Inc. Common Stock
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Market Statistics
Trading Metrics
How to Buy ELTX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ELTX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesElicio Therapeutics granted 30,300 inducement stock options to a new employee on February 17, 2026, at an exercise price of $8.59 per share. The options vest over four years with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, subject to continued employment.
Elicio Therapeutics granted 22,400 inducement stock options to two new employees on January 15, 2026, at an exercise price of $7.81 per share. The options vest over four years with 25% vesting on the first anniversary and the remainder vesting ratably monthly thereafter.
Elicio Therapeutics announced successful results for its ELI-002 off-the-shelf cancer vaccine, which induced mKRAS-specific T cell responses in 99% of evaluable patients. The vaccine targets common KRAS mutations in solid tumors and showed promising survival outcomes in pancreatic and colorectal cancer patients.
Elicio Therapeutics published extended follow-up data for its ELI-002 cancer vaccine, showing promising results in treating minimal residual disease-positive patients with pancreatic and colorectal cancers, with significant reductions in death and relapse risks.